EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

Relative Efficacy of Next‐Generation Incretin Therapies for Cardio‐Renal Protection in Type 2 Diabetes: Evidence From a Network Meta‐Analysis

Thi-Phuong-Thao Pham, Thi-Minh-Nhat Vo, The-Anh Nguyen, Tien-Phat Dao, Ngoc-Phuoc Ngo, Thi-Thuy-Duong Le, Thanh-Thien Tran, Thanh-Huong Pham, Dang-Mai-Linh Huynh, Hai-Anh Ha iD

Diabetes, Obesity and Metabolism · 2026-06 · 28 (6) · 4630-4652

DOI: 10.1111/dom.70635 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.03.2026. Verfasst von Thi-Phuong-Thao Pham und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, School of Pharmacy, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Incretins, Hypoglycemic Agents, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes (T2D) management has shifted towards integrated cardiometabolic and renal risk reduction. Although glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and newer dual agonists show promising benefits, comparative evidence across agents and outcomes remains limited.

Objectives

To compare the cardiovascular and renal effects of modern GLP‐1RAs (dulaglutide, semaglutide, lixisenatide), tirzepatide and cotadutide in high‐risk T2D populations, and to explore multivariate relationships among clinical outcomes.

Methods

A systematic review and network meta‐analysis was conducted following PRISMA and Cochrane guidance (PROSPERO: CRD42024592825). Randomised controlled trials published between 2014 and 2025 with ≥ 6 months follow‐up were included. Outcomes were cardiovascular death, myocardial infarction (MI), stroke, total major adverse cardiovascular events (MACE), eGFR and UACR. Random‐ and common‐effects models were applied using netmeta (R). Treatment rankings were estimated using p ‐scores. Inconsistency, heterogeneity and small‐study effects were evaluated. Correlation networks and principal component analysis (PCA) were performed to characterise interrelationships among clinical variables.

Results

Thirty‐four trials were included, predominantly multinational CVOTs and CKD‐focused studies. Semaglutide regimens showed the most consistent reduction in MACE and MI versus placebo, with the strongest effect observed for semaglutide combined with SGLT2 inhibition. Dulaglutide 1.5 mg and tirzepatide 15 mg significantly reduced stroke risk. Cardiovascular death estimates were largely imprecise with evidence of small‐study effects. Renal effects differed by endpoint: eGFR changes were generally modest, whereas UACR showed marked reductions, particularly with dulaglutide plus dapagliflozin, DPP‐4 inhibitors and semaglutide 1 mg. PCA confirmed strong cardiometabolic‐renal interdependence.

Conclusions

Cardiovascular and renal benefits of GLP‐1‐based therapies are outcome‐specific. Semaglutide favoured MACE/MI reduction, dulaglutide and tirzepatide supported stroke prevention, and albuminuria outcomes were more responsive than eGFR. Further long‐term head‐to‐head trials are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2IncretinsHypoglycemic AgentsDiabetic NephropathiesCardiovascular DiseasesHumansSemaglutideTirzepatideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsTreatment OutcomeRandomized Controlled Trials as TopicMyocardial InfarctionGlucagon-Like Peptide 1

Stichwörter der Autor:innen

GLP‐1 receptor agonistscardiovascular outcomesdual‐pathway incretin therapiesnetwork meta‐analysisrenal outcomestype 2 diabetes

Substanzen

IncretinsSemaglutideTirzepatideGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsdulaglutideRecombinant Fusion Proteinslixisenatide

Autor:innen und Institutionen

  • Pharmacy Department, School of Pharmacy, China Medical University, Taichung, Taiwan.
  • Faculty of Pharmacy, College of Pharmacy and Medicine, Duy Tan University, Da Nang, Vietnam.
  • Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
  • Department of Acupuncture, Vietnam University of Traditional Medicine, Hanoi, Vietnam.
  • International Public Health Department, China Medical University, Taichung, Taiwan.
  • Faculty of Pharmacy, Da Nang University of Medical Technology and Pharmacy, Da Nang, Vietnam.

ORCID-Profile: Hai-Anh Ha

Zitieren

APA

Pham, T. P., Vo, T. M., Nguyen, T. A., Dao, T. P., Ngo, N. P., Le, T. T., Tran, T. T., Pham, T. H., Huynh, D. M., & Ha, H. A. (2026). Relative Efficacy of Next‐Generation Incretin Therapies for Cardio‐Renal Protection in Type 2 Diabetes: Evidence From a Network Meta‐Analysis. Diabetes, Obesity and Metabolism, 28(6), 4630-4652. https://doi.org/10.1111/dom.70635

Vancouver

Pham TP, Vo TM, Nguyen TA, Dao TP, Ngo NP, Le TT, et al. Relative Efficacy of Next‐Generation Incretin Therapies for Cardio‐Renal Protection in Type 2 Diabetes: Evidence From a Network Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026;28(6):4630-4652. doi:10.1111/dom.70635

BibTeX
@article{Pham2026,
  author = {Pham, Thi-Phuong-Thao and Vo, Thi-Minh-Nhat and Nguyen, The-Anh and Dao, Tien-Phat and Ngo, Ngoc-Phuoc and Le, Thi-Thuy-Duong and Tran, Thanh-Thien and Pham, Thanh-Huong and Huynh, Dang-Mai-Linh and Ha, Hai-Anh},
  title = {Relative Efficacy of Next‐Generation Incretin Therapies for Cardio‐Renal Protection in Type 2 Diabetes: Evidence From a Network Meta‐Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {6},
  pages = {4630--4652},
  doi = {10.1111/dom.70635}
}
Kostenlos starten →